Models of Rheumatoid Arthritis

  • R. O. Williams
Part of the Ernst Schering Research Foundation Workshop book series (SCHERING FOUND, volume 50)


Cartilage Oligomeric Matrix Protein Adjuvant Arthritis Human Rheumatoid Arthritis Cartilage Oligomeric Matrix Protein Antiarthritic Drug 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Banerjee S, Wei BY, Hillman K, Luthra HS, David CS (1988) Immunosuppression of collagen-induced arthritis in mice with an anti-IL-2 receptor antibody. J Immunol 141:1150–1154PubMedGoogle Scholar
  2. Bedwell AE, Elson CJ, Hinton CE (1987) Immunological involvement in the pathogenesis of pristane-induced arthritis. Scand J Immunol 25:393–398PubMedCrossRefGoogle Scholar
  3. Boissier MC, Feng XZ, Carlioz A, Roudier R, Fournier C (1987) Experimental autoimmune arthritis in mice. I. Homologous type II collagen is responsible for self-perpetuating chronic polyarthritis. Ann Rheumatic Dis 46:691–700CrossRefGoogle Scholar
  4. Brackertz D, Mitchell GF, Mackay IR (1977) Antigen-induced arthritis in mice. I. Induction of arthritis in various strains of mice. Arthritis Rheum 20:841–850PubMedCrossRefGoogle Scholar
  5. Brahn E, Trentham DE (1984) Effect of antithymocyte serum on collagen arthritis in rats: evidence that T cells are involved in its pathogenesis. Cellular Immunology 86:421–428PubMedCrossRefGoogle Scholar
  6. Brennan FM, Chantry D, Jackson A, Maini R, Feldmann M (1989) Inhibitory effect of TNFα antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 2:244–247PubMedCrossRefGoogle Scholar
  7. Busso N, Peclat V, Van Ness K, Kolodziesczyk E, Degen J, Bugge T, So A (1998) Exacerbation of antigen-induced arthritis in urokinase-deficient mice. J Clin Invest 102:41–50PubMedCrossRefGoogle Scholar
  8. Butler DM, Malfait AM, Mason LJ, Warden PJ, Kollias G, Maini RN, Feldmann M, Brennan FM (1997) DBA/1 mice expressing the human TNF-alpha transgene develop a severe, erosive arthritis: characterization of the cytokine cascade and cellular composition. J Immunol 159:2867–2876PubMedGoogle Scholar
  9. Carlsen S, Hansson AS, Olsson H, Heinegard E, Holmdahl R (1998) Cartilage oligomeric matrix protein (COMP)-induced arthritis in rats. Clin Exp Immunol 114:477–484PubMedCrossRefGoogle Scholar
  10. Chang YH, Pearson CM, Abe C (1980) Adjuvant polyarthritis. IV. Induction by a synthetic adjuvant: immunologic, histopathologic, and other studies. Arthritis Rheum 23:62–71PubMedCrossRefGoogle Scholar
  11. Cobbold SP, Jayasuriya A, Nash A, Prospero TD, Waldmann H (1984) Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo. Nature 312:548–551PubMedCrossRefGoogle Scholar
  12. Cooper SM, Sriram S, Ranges GE (1988) Suppression of murine collagen-induced arthritis with monoclonal anti-Ia antibodies and augmentation with IFN-gamma. Journal of Immunology 141:1958–1962Google Scholar
  13. Dumonde DC, Glynn LE (1962) The production of arthritis in rabbits by an immunological reaction to fibrin. British Journal of Experimental Pathology 43:373–383PubMedGoogle Scholar
  14. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, Brennan FM, Walker J, Bijl H, Ghrayeb J, Woody JN (1993) Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumour necrosis factor a. Arthritis Rheum 36:1681–1690PubMedCrossRefGoogle Scholar
  15. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Bijl H, Woody JN (1994a) Repeated therapy with a monoclonal antibody to tumour necrosis factor α in patients with rheumatoid arthritis. Lancet 344:1125–1127PubMedCrossRefGoogle Scholar
  16. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smollen JS, Leeb B, Breedfeld FC, Macfarlane JD, Bijl H, Woody JN (1994b) Treatment with a chimaeric monoclonal antibody to tumour necrosis factor α suppresses disease activity in rheumatoid arthritis: results of a multi-centre, randomised, double blind trial. Lancet 344:1105–1110PubMedCrossRefGoogle Scholar
  17. Finnegan A, Mikecz K, Tao P, Giant TT (1999) Proteoglycan (aggrecan)-induced arthritis in BALB/c mice is a Th1-type disease regulated by Th2 cytokines. J Immunol 163:5383–5390PubMedGoogle Scholar
  18. Galfre G, Milstein C, Wright B (1979) Rat x rat hybrid myelomas and a monoclonal anti-Fd portion of mouse IgG. Nature 277:131–133PubMedCrossRefGoogle Scholar
  19. Geiger T, Towbin H, Cosenti-Vargas A, Zingel O, Arnold J, Rordorf C, Vos-beck K (1993) Neutralization of interleukin-1β activity in vivo with a monoclonal antibody alleviates collagen-induced arthritis in DBA/1 mice and prevents the associated acute-phase response. Clin Exp Rheumatol 11:515–522PubMedGoogle Scholar
  20. Giant TT, Mikecz K, Arzoumanian A, Poole AR (1987) Proteoglycan-in-duced arthritis in BALB/c mice. Clinical features and histopathology. Arthritis Rheum 30:201–212CrossRefGoogle Scholar
  21. Giant TT, Fulop C, Mikecz K, Buzas E, Molnar G, Erhardt P (1990) Proteoglycan-specific autoreactive antibodies and T-lymphocytes in experimental arthritis and human rheumatoid joint diseases. Biochemical Society Transactions 18:796–799Google Scholar
  22. Goldschmidt TJ, Holmdahl R (1991) Anti-T cell receptor antibody treatment of rats with established autologous collagen-induced arthritis: suppression of arthritis without reduction of anti-type II collagen autoantibody levels. European Journal of Immunology 21:1327–1330PubMedCrossRefGoogle Scholar
  23. Hegen M, Sun L, Uozumi N, Kume K, Goad ME, Nickerson-Nutter CL, Shimizu T, Clark JD (2003) Cytosolic phospholipase A2alpha-deficient mice are resistant to collagen-induced arthritis. J Exp Med 197:1297–1302PubMedCrossRefGoogle Scholar
  24. Holmdahl R, Jansson L, Larsson E, Rubin K, Klareskog L (1986) Homologous type II collagen induces chronic and progressive arthritis in mice. Arthritis & Rheumatism 29:106–113CrossRefGoogle Scholar
  25. Holmdahl R, Goldschmidt TJ, Kleinau S, Kvick C, Jonsson R (1992) Arthritis induced in rats with adjuvant oil is a genetically restricted, alpha beta T-cell dependent autoimmune disease. Immunology 76:197–202PubMedGoogle Scholar
  26. Holmdahl R, Andersson ME, Goldschmidt TJ, Jansson L, Karlsson M, Malmström V, Mo J (1989) Collagen induced arthritis as an experimental model for rheumatoid arthritis. Immunogenetics, pathogenesis and autoimmunity. APMIS 97:575–584PubMedGoogle Scholar
  27. Horn JT, Butler LD, Riedl PE, Bendele AM (1988) The progression of the inflammation in established collagen-induced arthritis can be altered by treatments with immunological or pharmacological agents which inhibit T cell activities. European Journal of Immunology 18:881–888CrossRefGoogle Scholar
  28. Jabs DA, Kuppers RC, Saboori AM, Burek CL, Enger C, Lee B (1994) Effects of early and late treatment with anti-CD4 monoclonal antibody on autoimmune disease in MRL/MP-lpr/lpr mice. Cellular Immunology 154:66–76PubMedCrossRefGoogle Scholar
  29. Joosten LAB, Helen MMA, van de Loo FAJ, Van den Berg WB (1996) Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-TNFα, anti-IL-1α/β, and IL-lRa. Arthritis & Rheumatism 39:797–809CrossRefGoogle Scholar
  30. Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, Kollias G (1991) Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. Embo Journal 10:4025–4031PubMedGoogle Scholar
  31. Kleinau S, Klareskog L (1993) Oil-induced arthritis in DA rats passive transfer by T cells but not with serum. Journal of Autoimmunity 6:449–458PubMedCrossRefGoogle Scholar
  32. Kleinau S, Erlandsson H, Klareskog L (1994) Percutaneous exposure of adjuvant oil causes arthritis in DA rats. Clinical & Experimental Immunology 96:281–284Google Scholar
  33. Kohashi O, Aihara K, Ozawa A, Kotani S, Azuma I (1982) New model of a synthetic adjuvant, N-acetylmuramyl-L-alanyl-D-isoglutamine-induced arthritis: clinical and histologic studies in athymic nude and euthymic rats. Lab Invest 47:27–36PubMedGoogle Scholar
  34. Kollias G, Douni E, Kassiotis G, Kontoyiannis D (1999) On the role of tumor necrosis factor and receptors in models of multiorgan failure, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Immunol Rev 169:175–194PubMedCrossRefGoogle Scholar
  35. Kontoyiannis D, Pasparakis M, Pizarro TT, Cominelli F, Kollias G (1999) Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity 10:387–398PubMedCrossRefGoogle Scholar
  36. Korganow AS, Ji H, Mangialaio S, Duchatelle V, Pelanda R, Martin T, Degott C, Kikutani H, Rajewsky K, Pasquali JL, Benoist C, Mathis D (1999) From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins. Immunity 10:451–461PubMedCrossRefGoogle Scholar
  37. Kouskoff V, Korganow AS, Duchatelle V, Degott C, Benoist C, Mathis D (1996) Organ-specific disease provoked by systemic autoimmunity. Cell 87:811–822PubMedCrossRefGoogle Scholar
  38. Larsson P, Holmdahl R, Dencker L, Klareskog L (1985) In vivo treatment with W3/13 (anti-pan T) but not with 0X8 (anti-suppressor/cytotoxic T) monoclonal antibodies impedes the development of adjuvant arthritis in rats. Immunology 56:383–391PubMedGoogle Scholar
  39. Lorentzen JC, Klareskog L (1996) Susceptibility of DA rats to arthritis induced with adjuvant oil or rat collagen is determined by genes both within and outside the major histocompatibility complex. Scand J Immunol 44:592–598PubMedCrossRefGoogle Scholar
  40. Maeda T, Saikawa I, Hotokebuchi T, Sugioka Y, Eto M, Murakami Y (1994) Exacerbation of established collagen-induced arthritis in mice treated with an anti-T cell receptor antibody. Arthritis & Rheumatism 37:406–413CrossRefGoogle Scholar
  41. Maini RN, Elliott M, Brennan FM, Williams RO, Feldmann M (1997) TNF blockade in rheumatoid arthritis: implications for therapy and pathogenesis. APMIS 105:257–263PubMedCrossRefGoogle Scholar
  42. Malfait AM, Williams RO, Malik AS, Maini RN, Feldmann M (2001) Chronic relapsing homologous collagen-induced arthritis in DBA/1 mice as a model for testing disease-modifying and remission-inducing therapies. Arthritis Rheum 44:1215–1224PubMedCrossRefGoogle Scholar
  43. Malfait A-M, Butler DM, Presky DH, Maini RN, Brennan FM, Feldmann M (1998) Blockade of IL-12 during the induction of collagen-induced arthritis (CIA) markedly attenuates the severity of the arthritis. Clin Exp Immunol 111:377–383PubMedCrossRefGoogle Scholar
  44. Mangialaio S, Ji H, Korganow AS, Kouskoff V, Benoist C, Mathis D (1999) The arthritogenic T cell receptor and its ligand in a model of spontaneous arthritis. Arthritis Rheum 42:2517–2523PubMedCrossRefGoogle Scholar
  45. Marinova-Mutafchieva L, Williams RO, Mason LJ, Mauri C, Feldmann M, Maini RN (1997) Dynamics of proinflammatory cytokine expression in the joints of mice with collagen-induced arthritis (CIA). Clinical & Experimental Immunology 107:507–512CrossRefGoogle Scholar
  46. Matsumoto I, Staub A, Benoist C, Mathis D (1999) Arthritis provoked by linked T and B cell recognition of a glycolytic enzyme. Science 286: 1732–1735PubMedCrossRefGoogle Scholar
  47. Matsumoto I, Maccioni M, Lee DM, Maurice M, Simmons B, Brenner M, Mathis D, Benoist C (2002) How antibodies to a ubiquitous cytoplasmic enzyme may provoke joint-specific autoimmune disease. Nat Immunol 3:360–365PubMedCrossRefGoogle Scholar
  48. Mauri C, Chu CQ, Woodrow D, Mori L, Londei M (1997) Treatment of a newly established transgenic model of chronic arthritis with nondepleting anti-CD4 monoclonal antibody. Journal of Immunology 159:5032–5041Google Scholar
  49. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, Ettlinger RE, Cohen S, Koopman WJ, Mohler K, Widmer MB, Blosch CM (1997) Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. New England Journal of Medicine 337:141–147PubMedCrossRefGoogle Scholar
  50. Mori L, Loetscher H, Kakimoto K, Bluethmann H, Steinmetz M (1992) Expression of a transgenic T cell receptor β chain enhances collagen-induced arthritis. Journal of Experimental Medicine 176:381–388PubMedCrossRefGoogle Scholar
  51. Niki Y, Yamada H, Seki S, Kikuchi T, Takaishi H, Toyama Y, Fujikawa K, Tada N (2001) Macrophage-and neutrophil-dominant arthritis in human IL-1 alpha transgenic mice. J Clin Invest 107:1127–1135PubMedCrossRefGoogle Scholar
  52. Nordquist N, Olofsson P, Vingsbo-Lundberg C, Petterson U, Holmdahl R (2000) Complex genetic control in a rat model for rheumatoid arthritis. J Autoimmun 15:425–432PubMedCrossRefGoogle Scholar
  53. Ochi T, Ohkubo Y, Mutoh S (2003) Role of cyclooxygenase-2, but not cy-clooxygenase-1, on type II collagen-induced arthritis in DBA/1 J mice. Biochem Pharmacol 66:1055–1060PubMedCrossRefGoogle Scholar
  54. Olofsson P, Holmberg J, Tordsson J, Lu S, Akerstrom B, Holmdahl R (2003) Positional identification of Ncfl as a gene that regulates arthritis severity in rats. Nat Genet 33:25–32PubMedCrossRefGoogle Scholar
  55. Olofsson P, Nordquist N, Vingsbo-Lundberg C, Larsson A, Falkenberg C, Pettersson U, Akerstrom B, Holmdahl R (2002) Genetic links between the acute-phase response and arthritis development in rats. Arthritis Rheum 46:259–268PubMedCrossRefGoogle Scholar
  56. Ozegbe P, Foey AD, Ahmed S, Williams RO (2003) Impact of cAMP on the T cell response to type II collagen. Immunol (in press)Google Scholar
  57. Pearson CM (1956) Development of arthritis, periarthritis and periostitis in rats given adjuvants. Proc Soc Exp Biol Med 91:95–101PubMedGoogle Scholar
  58. Peccoud J, Dellabona P, Allen P, Benoist C, Mathis D (1990) Delineation of antigen contact residues on an MHC class II molecule. Embo J 9:4215–4223PubMedGoogle Scholar
  59. Piguet PF, Grau GE, Vesin C, Loetscher H, Gentz R, Lesslauer W (1992) Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor. Immunol 77:510–514Google Scholar
  60. Probert L, Plows D, Kontogeorgos G, Kollias G (1995) The type I interleu-kin-1 receptor acts in series with tumor necrosis factor (TNF) to induce arthritis in TNF-transgenic mice. European Journal of Immunology 25: 1794–1797PubMedCrossRefGoogle Scholar
  61. Qin S, Cobbold S, Tighe H, Benjamin R, Waldmann H (1987) CD4 monoclonal antibody pairs for immunosuppression and tolerance induction. European Journal of Immunology 17:1159–1165PubMedCrossRefGoogle Scholar
  62. Ranges GE, Sriram S, Cooper SM (1985) Prevention of type II collagen-induced arthritis by in vivo treatment with anti-L3T4. Journal of Experimental Medicine 162:1105–1110PubMedCrossRefGoogle Scholar
  63. Rankin ECC, Choy EHS, Kassimos D, Kingsley GH, Sopwith AM, Isenberg DA, Panayi GS (1995) The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. British Journal of Rheumatology 34:334–342PubMedCrossRefGoogle Scholar
  64. Remmers EF, Longman RE, Du Y, O’Hare A, Cannon GW, Griffiths MM, Wilder RL (1996) A genome scan localizes five non-MHC loci controlling collagen-induced arthritis in rats. Nat Genet 14:82–85PubMedCrossRefGoogle Scholar
  65. Saklatvala J, Sarsfield SJ, Townsend Y (1985) Pig interleukin 1. Purification of two immunologically different leukocyte proteins that cause cartilage resorption, lymphocyte activation, and fever. J Exp Med 162:1208–1222PubMedCrossRefGoogle Scholar
  66. Saklatvala J, Pilsworth LM, Sarsfield SJ, Gavrilovic J, Heath JK (1984) Pig catabolin is a form of interleukin 1. Cartilage and bone resorb, fibroblasts make prostaglandin and collagenase, and thymocyte proliferation is augmented in response to one protein. Biochem J 224:461–466PubMedGoogle Scholar
  67. Sheehan KC, Ruddle NH, Schreiber RD (1989) Generation and characterization of hamster monoclonal antibodies that neutralize murine tumor necrosis factors. Journal of Immunology 142:3884–3893Google Scholar
  68. Sternberg EM, Hill JM, Chrousos GP, Kamilaris T, Listwak SJ, Gold PW, Wilder RL (1989) Inflammatory mediator-induced hypothalamic-pituitary-adrenal axis activation is defective in streptococcal cell wall arthritis-susceptible Lewis rats. Proc Natl Acad Sci USA 86:2374–2378PubMedCrossRefGoogle Scholar
  69. Sternberg EM, Young WS, Bernardini R, Calogero AE, Chrousos GP, Gold PW, Wilder RL (1989) A central nervous system defect in biosynthesis of corticotropin-releasing hormone is associated with susceptibility to streptococcal cell wall-induced arthritis in Lewis rats. Proc Natl Acad Sci USA 86:4771–4775PubMedCrossRefGoogle Scholar
  70. Svelander L, Mussener A, Erlandsson-Harris H, Kleinau S (1997) Polyclonal Thl cells transfer oil-induced arthritis. Immunology 91:260–265PubMedCrossRefGoogle Scholar
  71. Sverdrup B, Klareskog L, Kleinau S (1998) Common Commercial Cosmetic Products Induce Arthritis in the DA Rat. Environ Health Perspect 106: 27–32PubMedCrossRefGoogle Scholar
  72. Thorbecke GJ, Shah R, Leu CH, Kuruvilla AP, Hardison AM, Palladino MA (1992) Involvement of endogenous tumor necrosis factor a and transforming growth factor β during induction of collagen type II arthritis in mice. Proceedings of the National Academy of Sciences of the United States of America 89:7375–7379PubMedCrossRefGoogle Scholar
  73. Trentham DE (1982) Collagen arthritis as a relevant model for rheumatoid arthritis: evidence pro and con. Arthritis & Rheumatism 25:911–916CrossRefGoogle Scholar
  74. Van den Berg WB, Joosten LA, Helsen M, van de Loo FA (1994) Amelioration of established murine collagen-induced arthritis with anti-IL-1 treatment. Clinical & Experimental Immunology 95:237–243Google Scholar
  75. Van Eden W, Thole JE, Van der Zee R, Noordzij A, van Embden JD, Cohen IR (1988) Cloning of the mycobacterial epitope recognized by T lymphocytes in adjuvant arthritis. Nature 331:171–173PubMedCrossRefGoogle Scholar
  76. Vingsbo C, Jonsson R, Holmdahl R (1995) Avridine-induced arthritis in rats; a T cell-dependent chronic disease influenced both by MHC genes and by non-MHC genes. Clinical & Experimental Immunology 99:359–363Google Scholar
  77. Vingsbo-Lundberg C, Nordquist N, Olofsson P, Sundvall M, Saxne T, Pet-tersson U, Holmdahl R (1998) Genetic control of arthritis onset, severity and chronicity in a model for rheumatoid arthritis in rats. Nat Genet 20:401–404PubMedCrossRefGoogle Scholar
  78. Waldmann TA (1991) Monoclonal antibodies in diagnosis and therapy. Science 252:1657–1662PubMedCrossRefGoogle Scholar
  79. Warren HS, Vogel FR, Chedid LA (1986) Current status of immunological adjuvants. Annu Rev Immunol 4:369–388PubMedCrossRefGoogle Scholar
  80. Webb LM, Walmsley MJ, Feldmann M (1996) Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 co-stimulatory pathway: requirement for both B7-1 and B7-2. European Journal of Immunology 26:2320–2328PubMedCrossRefGoogle Scholar
  81. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, Jackson CG, Lange M, Burge DJ (1999) A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. New England Journal of Medicine 340:253–259PubMedCrossRefGoogle Scholar
  82. Williams RO, Feldmann M, Maini RN (1992) Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 89:9784–9788PubMedCrossRefGoogle Scholar
  83. Williams RO, Mason LJ, Feldmann M, Maini RN (1994) Synergy between anti-CD4 and anti-TNF in the amelioration of established collagen-induced arthritis. Proc Natl Acad Sci USA 91:2762–2766PubMedCrossRefGoogle Scholar
  84. Williams RO, Ghrayeb J, Feldmann M, Maini RN (1995) Successful therapy of collagen-induced arthritis with TNF receptor-IgG fusion protein and combination with anti-CD4. Immunology 84:433–439PubMedGoogle Scholar
  85. Williams RO, Mauri C, Mason LJ, Marinova-Mutafchieva L, Ross SE, Feldmann M, Maini RN (1998) Therapeutic actions of cyclosporin and anti-TNFα in collagen-induced arthritis and effect of combination therapy. Arthritis & Rheumatism 41:1806–1812CrossRefGoogle Scholar
  86. Wooley PH, Dutcher J, Widmer MB, Gillis S (1993) Influence of a recombinant human soluble tumour necrosis factor receptor Fc fusion protein on type II collagen-induced arthritis in mice. Journal of Immunology 151:6602–6607Google Scholar
  87. Wooley PH, Luthra HS, Lafuse WP, Huse A, Stuart JM, David CS (1985) Type II collagen-induced arthritis in mice. III. Suppression of arthritis by using monoclonal and polyclonal anti-Ia antisera. Journal of Immunology 134:2366–2374Google Scholar
  88. Yoshino S, Cleland LG (1992) Depletion of α/β T cells by a monoclonal antibody against the α/β T cell receptor suppresses established adjuvant arthritis, but not established collagen-induced arthritis in rats. Journal of Experimental Medicine 175:907–915PubMedCrossRefGoogle Scholar
  89. Yoshino S, Cleland LG, Mayrhofer G (1991) Treatment of collagen-induced arthritis in rats with a monoclonal antibody against the alpha/beta T cell antigen receptor. Arthritis & Rheumatism 34:1039–1047CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2005

Authors and Affiliations

  • R. O. Williams
    • 1
  1. 1.Faculty of Medicine Imperial college of Science Technology and MedicineKennedy Institute of Rheumatology DivisionHammersmith LondonUK

Personalised recommendations